[Author note slot — one honest line of first-hand credibility, e.g. “I’ve managed paid acquisition for regulated e-commerce for X years and currently run live Meta and Google accounts for US & UK research peptide brands. This is the exact standard we hold every campaign to.”] This is where Experience is demonstrated — replace the bracketed text with real specifics before publishing.
Almost every “banned peptide ad account” post-mortem lands on the same root cause, and it isn’t the product. It’s a claim, a landing page, or an account setup that told the platform the product was for human consumption. Get that one dimension right and the picture changes entirely.
The line that decides everything: research-grade peptides advertised for laboratory and research use occupy a permitted lane. The moment an ad or its landing page implies human use — dosing, health outcomes, before/afters — it collides with healthcare and pharmaceutical policy. Compliant peptide advertising is the discipline of never crossing that line, anywhere in the funnel.
Why accounts actually get banned
In our experience running live accounts, disapprovals cluster into four causes, and none of them are “you advertised a peptide”:
- Human-use claims in copy. Dosage, benefits, “results”, testimonials about how someone felt — anything implying consumption.
- Landing-page mismatch. A clean ad pointing to a page that then makes health claims. Reviewers check the destination.
- Account and category setup. Wrong business category, missing verification, or a history that flags the advertiser as high-risk.
- Evasion signals. Cloaking, doorway pages and rotated accounts — the very tactics meant to dodge review are what trigger permanent bans.
The compliant setup, step by step
1. Fix the copy first
[Explain your real process: research-use-only framing, what language is removed, how creative is briefed. Add a genuine example of a rewritten line — before/after — from your own work.]
2. Make the landing page match
[Describe how the destination holds the same line: RUO labelling, no health claims, consistent with the ad. Note that this is where most agencies fail.]
3. Set the account up properly
[Business verification, correct categorisation, policy-aligned structure. Legitimate accounts built to pass review.]
4. Monitor and adapt
[How you track policy changes and pre-empt disapprovals, with weekly reporting.]
What we never do: cloaking, doorway pages, account rotation or re-warming, or any human-use claim to sneak past review. These mark an advertiser as high-risk and lead to permanent loss of the asset. Sustainable beats fast.
Pair paid with channels you own
Even a perfectly compliant account lives on rented land. The brands that win treat paid ads as the top of a funnel that captures email subscribers and improves through CRO, so the traffic you pay for becomes an asset you keep. If an account is ever disrupted, the business doesn’t stop with it.
A necessary disclaimer
We’re marketers, not lawyers. Platform policies and UK regulations (ASA/CAP, and MHRA rules on unlicensed medicines) change and are applied case by case, and some compounds sit in a tighter regulatory position than others. For any product where regulatory status is unclear, have qualified counsel review before scaling spend. Nothing here is legal advice.